Invvax, Inc.
Cypress, CA Doing business as Invvax Inc.
- UEI
- XD11NMF7NB14
- CAGE
- 6V1X5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 4846 Tremezzo Dr, Cypress, CA 90630, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase II: stable prophylactic antibodies -the broader impact of this small business innovation research (sbir)… | National Science Foundation | $996,606 | |
| Invariance mapping of the complete HBV genome and testing of MRE11 repair nuclease toward the improvement of… | Medical Command | $1,878,970 | |
| Sbir phase i: stable prophylactic antibodies -the broader impact/commercial potential of this small business… | Division of Industrial Innovation | $255,927 |
About Invvax, Inc.
Invvax, Inc. is a corporate, for-profit organization registered in SAM.gov since March 2013, with registration valid through July 2026. The company appears to be a biotechnology research firm focused on developing innovative medical solutions, particularly in the realm of antibody engineering and infectious disease prevention. Primarily operating through Small Business Innovation Research (SBIR) grants, Invvax, Inc. specializes in advanced biotechnological research that aims to create transformative medical technologies with potential widespread healthcare applications.
The company has received multiple federal grants from agencies like the National Science Foundation (NSF) and the Department of the Army Medical Command, focusing on developing stable prophylactic antibodies (SPABs) and advanced gene therapy approaches. Specifically, Invvax, Inc. has been awarded grants to conduct research on extending antibody stability for preventing infectious diseases such as influenza, malaria, tuberculosis, HIV, and the common cold. In one significant project with the Department of the Army, the company received $1,878,970 to research genome mapping of the hepatitis B virus and improve CRISPR/Cas gene therapy techniques. Another NSF-funded project involves engineering antibody mutations to resist degradation and enhance receptor binding, with the ultimate goal of creating long-lasting preventative treatments that could potentially be administered once in a lifetime. These grants, ranging from $255,927 to $1,878,970, demonstrate Invvax's commitment to innovative medical research with potential broad-scale healthcare implications.
Quick answers
What is Invvax, Inc.'s UEI?
Invvax, Inc.'s Unique Entity ID (UEI) in SAM.gov is XD11NMF7NB14.
What is Invvax, Inc.'s CAGE code?
Invvax, Inc.'s CAGE code is 6V1X5.
What is Invvax, Inc.'s primary NAICS code?
Invvax, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Invvax, Inc. located?
Invvax, Inc.'s physical address in SAM.gov is 4846 Tremezzo Dr, Cypress, CA 90630, USA.
Is Invvax, Inc. registered in SAM.gov?
Yes. Invvax, Inc.'s SAM.gov registration is active through July 2, 2027.
What is Invvax, Inc.'s most recent federal award?
Invvax, Inc.'s most recent federal grant award is Sbir phase II: stable prophylactic antibodies -the broader impact of this small business innovation research (sbir)… (2422363), from National Science Foundation, on July 1, 2025.
On GovTribe
See Invvax, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors